<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04153279</url>
  </required_header>
  <id_info>
    <org_study_id>HXYT-005</org_study_id>
    <nct_id>NCT04153279</nct_id>
  </id_info>
  <brief_title>CMV-TCR-T Cells for CM Virus Infection After HSCT</brief_title>
  <official_title>A Pilot Study of CMV-TCR-T Cells in CM Virus Infection Diseases After HSCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Yanda Ludaopei Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>China Immunotech (Beijing) Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hebei Yanda Ludaopei Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single cente, single arm, open-label, phase I study to evaluate the safety and&#xD;
      effectiveness of CMV-TCR-T cell immunotherapy in treating CMV virus infection after HSCT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CMV infection is a common virus infection of HSCT, and which is highly related with the&#xD;
      failure of transplantation and survival time of transplant patients. To evaluate the safety&#xD;
      and efficacy of allogenic CMV-TCR-T cell therapy in subjects with CMV infection, patients&#xD;
      with CMV emias or deseases will be enrolled, and donor derived&#xD;
      CMV-TCR-T(HLA-A*1101\0201\2402) cells will be intravenously infused with a escalated dose of&#xD;
      0.1-1×106 CMV-TCR-T cells. The CMV DNA copies and CMV-TCR-T cell proliferation will be&#xD;
      monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14, day 28).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 19, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of adverse events</measure>
    <time_frame>3months</time_frame>
    <description>Percentage of participants with adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Persistence of TCR-T cells</measure>
    <time_frame>3months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of CMV-DNA copies number</measure>
    <time_frame>3months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>CMV Infection or Reactivation After Allogenic HSCT</condition>
  <arm_group>
    <arm_group_label>CMV-TCR-T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will receive one dose of CMV-TCR-T.The dosage ranges from 0.1×10^6 to 1×10^6 TCR+T/Kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CMV-TCR-T cells</intervention_name>
    <description>Patients with CMV emias or CMV disease will be enrolled, and donor derived CMV-TCR-T(HLA-A*1101\0201\2402) cells will be intravenously infused with a escalated dose of 0.1-1×106 CMV-TCR-T cells. The CMV DNA copies and CMV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14,day 28).</description>
    <arm_group_label>CMV-TCR-T cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 1-70 years, including boundary values, gender unlimited;&#xD;
&#xD;
          2. Allogenic hematopoietic stem cell transplantation patients with CMV infection disease&#xD;
             or persistent CMV emia;&#xD;
&#xD;
          3. At least one of the following conditions after allogeneic HSCT:&#xD;
&#xD;
               -  After trested with 2-week standard antiviral drug, compared to the baseline of&#xD;
                  treatment, the decrease of CMV DNA copies number was less than 1log10, and the&#xD;
                  CMV DNA copies number is greater than 1000 copies/ mL ;&#xD;
&#xD;
               -  Unable to tolerate the toxic and side effects of antiviral drugs,such as bone&#xD;
                  marrow hematopoietic suppression, nephrotoxicity;&#xD;
&#xD;
          4. Estimated life expectancy ≥3 months；&#xD;
&#xD;
          5. ECOG 3;&#xD;
&#xD;
          6. Patients who voluntarily sign informed consent and are willing to comply with&#xD;
             treatment plans, visit arrangements, laboratory tests and other research procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with active aGVHD III-IV and / or mild and severe cGVHD;&#xD;
&#xD;
          2. Received cell therapy such as DLI,CTL,CAR-T or participated in any other clinical&#xD;
             study of drugs and medical devices before 30 days of enrollment.&#xD;
&#xD;
          3. Pregnant or lactating women;&#xD;
&#xD;
          4. Intracranial hypertension or confusion; respiratory failure; disseminated&#xD;
             intravascular coagulation;&#xD;
&#xD;
          5. patients with organ failure:&#xD;
&#xD;
               -  Heart: NYHA heart function grade IV;&#xD;
&#xD;
               -  Liver: Grade C that achieves Child-Turcotte liver function grading;&#xD;
&#xD;
               -  Kidney: kidney failure and uremia;&#xD;
&#xD;
               -  Lung: symptoms of respiratory failure;&#xD;
&#xD;
               -  Brain: a person with a disability;&#xD;
&#xD;
          6. The researchers found that it was unsuitable for the recipients to be enrolled.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xingyu Cao, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Hebei Yanda Ludaopei Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xingyu Cao, Ph.D</last_name>
    <phone>+8619910757321</phone>
    <email>caoxingyu@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hebei Yanda Ludaopei Hospital</name>
      <address>
        <city>Sanhe</city>
        <state>Hebei</state>
        <zip>065200</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xingyu Cao, PhD</last_name>
      <phone>+8619910757321</phone>
      <email>caoxingyu@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>November 4, 2019</study_first_submitted>
  <study_first_submitted_qc>November 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2019</study_first_posted>
  <last_update_submitted>February 5, 2021</last_update_submitted>
  <last_update_submitted_qc>February 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

